The development of dilated cardiomyopathy in ErbB2-deficient mice and anti-HER2 (ErbB2)-targeted therapy patients suggests that the NRG-1/ErbB signaling pathway is implicated in the pathophysiology of heart failure [10]. Here, ERBB2 is linked to dilated cardiomyopathy.